Journal Article

DKFZ-2023-02095

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.

Fuchs, M. ; Jacob, A. S. ; Kaul, H. ; Kobe, C. ; Kuhnert, G. ; Pabst, T. ; Greil, R. ; Bröckelmann, P. J. ; Topp, M. S. ; Just, M. ; Hertenstein, B. ; Soekler, M. ; Vogelhuber, M. ; Zijlstra, J. M. ; Keller, U. B. ; Krause, S. W. ; Dührsen, U. ; Meissner, J. ; Viardot, A. ; Eich, H.-T. ; Baues, C. ; Diehl, V. ; Rosenwald, A. ; Buehnen, I. ; von Tresckow, B.DKFZ* ; Dietlein, M. ; Borchmann, P. ; Engert, A. ; Eichenauer, D. A.

2024
Springer Nature London

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41375-023-02064-y

Abstract: The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18-75 years with newly diagnosed early-stage favorable HL were randomized between standard combined-modality treatment (CMT) (2x ABVD followed by PET/CT [PET-2] and 20 Gy involved-field RT) and PET-2-guided treatment omitting RT in case of PET-2 negativity (Deauville score [DS] < 3). The study aimed at excluding inferiority of PET-2-guided treatment and assessing the prognostic impact of PET-2 in patients receiving CMT. At a median follow-up of 64 months, PET-2-negative patients had a 5-year progression-free survival (PFS) of 94.2% after CMT (n = 328) and 86.7% after ABVD alone (n = 300; HR = 2.05 [1.20-3.51]; p = 0.0072). 5-year OS was 98.3% and 98.8%, respectively (p = 0.14); 4/12 documented deaths were caused by second primary malignancies and only one by HL. Among patients assigned to CMT, 5-year PFS was better in PET-2-negative (n = 353; 94.0%) than in PET-2-positive patients (n = 340; 90.3%; p = 0.012). The difference was more pronounced when using DS4 as cut-off (DS 1-3: n = 571; 94.0% vs. DS ≥ 4: n = 122; 83.6%; p < 0.0001). Taken together, CMT should be considered standard treatment for early-stage favorable HL irrespective of the PET-2-result.

Note: 2024 Jan;38(1):160-167

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Essen/Düsseldorf (ED01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2023

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---